440 related articles for article (PubMed ID: 30511409)
1. Immune checkpoint blockade opens a new way to cancer immunotherapy.
Sadreddini S; Baradaran B; Aghebati-Maleki A; Sadreddini S; Shanehbandi D; Fotouhi A; Aghebati-Maleki L
J Cell Physiol; 2019 Jun; 234(6):8541-8549. PubMed ID: 30511409
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoints and cancer development: Therapeutic implications and future directions.
Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
[TBL] [Abstract][Full Text] [Related]
3. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
[TBL] [Abstract][Full Text] [Related]
4. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
Qin S; Xu L; Yi M; Yu S; Wu K; Luo S
Mol Cancer; 2019 Nov; 18(1):155. PubMed ID: 31690319
[TBL] [Abstract][Full Text] [Related]
5. [The "immune checkpoints", how does it work].
Granier C; Soumelis V; Mandavit M; Gibault L; Belazzoug R; de Guillebon E; Badoual C; Tartour E; Roussel H
Ann Pathol; 2017 Feb; 37(1):18-28. PubMed ID: 28160999
[TBL] [Abstract][Full Text] [Related]
6. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
7. ILT4 functions as a potential checkpoint molecule for tumor immunotherapy.
Gao A; Sun Y; Peng G
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):278-285. PubMed ID: 29649510
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy.
Rotte A; Jin JY; Lemaire V
Ann Oncol; 2018 Jan; 29(1):71-83. PubMed ID: 29069302
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the clinical development of immune checkpoint blockade therapy.
Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
[TBL] [Abstract][Full Text] [Related]
10. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
[No Abstract] [Full Text] [Related]
11. Targeting CTLA-4 in cancer: Is it the ideal companion for PD-1 blockade immunotherapy combinations?
De Silva P; Aiello M; Gu-Trantien C; Migliori E; Willard-Gallo K; Solinas C
Int J Cancer; 2021 Jul; 149(1):31-41. PubMed ID: 33252786
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint modulators in cancer immunotherapy: Recent advances and combination rationales.
Fan L; Li Y; Chen JY; Zheng YF; Xu XM
Cancer Lett; 2019 Aug; 456():23-28. PubMed ID: 30959079
[TBL] [Abstract][Full Text] [Related]
13. Development of Cancer Immunotherapy Targeting the PD-1 Pathway.
Kamimura N; Wolf AM; Iwai Y
J Nippon Med Sch; 2019; 86(1):10-14. PubMed ID: 30918149
[TBL] [Abstract][Full Text] [Related]
14. The blockade of immune checkpoints in cancer immunotherapy.
Pardoll DM
Nat Rev Cancer; 2012 Mar; 12(4):252-64. PubMed ID: 22437870
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint blockade therapy.
Wieder T; Eigentler T; Brenner E; Röcken M
J Allergy Clin Immunol; 2018 Nov; 142(5):1403-1414. PubMed ID: 29596939
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Hargadon KM; Johnson CE; Williams CJ
Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
[TBL] [Abstract][Full Text] [Related]
17. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoints and cancer in the immunogenomics era.
Park R; Winnicki M; Liu E; Chu WM
Brief Funct Genomics; 2019 Mar; 18(2):133-139. PubMed ID: 30137232
[TBL] [Abstract][Full Text] [Related]
19. Not All Immune Checkpoints Are Created Equal.
De Sousa Linhares A; Leitner J; Grabmeier-Pfistershammer K; Steinberger P
Front Immunol; 2018; 9():1909. PubMed ID: 30233564
[TBL] [Abstract][Full Text] [Related]
20. The application of nanotechnology in immune checkpoint blockade for cancer treatment.
Deng H; Zhang Z
J Control Release; 2018 Nov; 290():28-45. PubMed ID: 30287266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]